Literature DB >> 31524352

Dupilumab Treatment for Prurigo Nodularis and Pruritis

Ross Tanis, Katalin Ferenczi, Michael Payette.   

Abstract

Prurigo nodularis (PN) is a disease in which chronic scratching and picking of the skin due to intense pruritis results in papulonodules, notably in areas that are accessible to the patient. The pathophysiology is hypothesized to be mediated by a Th2 helper cell response, similar to that seen in atopic dermatitis, therefore, treatment of PN with dupilumab would be expected to elicit a therapeutic response. We demonstrated that treatment of PN with dupilumab significantly decreased pruritis and the size and number of new lesions after 2 months of treatment. J Drugs Dermatol. 2019;18(9):940-942.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31524352

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  3 in total

1.  TRPV1 in Pain and Itch.

Authors:  Fengxian Li; Fang Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.

Authors:  Micah Belzberg; Martin Prince Alphonse; Isabelle Brown; Kyle A Williams; Raveena Khanna; Byron Ho; Shannon Wongvibulsin; Thomas Pritchard; Youkyung Sophie Roh; Nishadh Sutaria; Justin Choi; Jaroslaw Jedrych; Andrew D Johnston; Kakali Sarkar; Chirag Vasavda; Jimmy Meixiong; Carly Dillen; Kent Bondesgaard; John F Paolini; Wei Chen; David Corcoran; Nicolas Devos; Madan M Kwatra; Anna L Chien; Nathan K Archer; Luis A Garza; Xinzhong Dong; Sewon Kang; Shawn G Kwatra
Journal:  J Invest Dermatol       Date:  2021-03-23       Impact factor: 7.590

Review 3.  Immunotargets and Therapy for Prurigo Nodularis.

Authors:  Angelina Labib; Teresa Ju; Ashley Vander Does; Gil Yosipovitch
Journal:  Immunotargets Ther       Date:  2022-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.